Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Breast Neoplasms, Breast Cancer, Adenocarcinomas or Metastatic Solid Tumors Characterized by HER2/Neu Expression
and you are
between 18 and 99
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

Background: - HER2/neu (HER2) is a tumor protein that appears in almost a third of breast cancers and in several other types of cancers such as colon, prostate and non-small cell lung. Tumors that overexpress HER2 can be associated with a more aggressive cancer, higher recurrence rates, and reduced survival rates. Researchers are testing a therapeutic cancer vaccine designed to stimulate the immune system to recognize HER2. The vaccine, called AdHER2/neu dendritic cell vaccine, is custom-made using an individual s own immune cells. These cells will be collected and used to produce the vaccine. Objectives: - To test the safety and effectiveness of AdHER2 vaccination. Eligibility: - Individuals at least 18 years of age who have HER2-expressing tumors. Design: - Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies will also be performed. - Participants will have an apheresis procedure to collect immune cells to create the vaccine. - Participants will receive four doses of the vaccine at study Weeks 0, 4, 8, and 24. - Participants will be monitored with physical exams, frequent blood tests and imaging studies.

Provided treatments

  • Biological: AdHER2/neu DC Vaccine
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01730118. The sponsor of the trial is National Cancer Institute (NCI) and it is looking for 65 volunteers for the current phase.
Official trial title:
A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/Neu ECTM in Adults With Tumors With 1-3+ HER2/Neu Expression